Serina Therapeutics, a clinical-stage biotechnology company, has announced a major development in the treatment of Tardive Dyskinesia (TD) by advancing its innovative POZ-VMAT2i candidate into clinical development. This move, reported by Drugs.com, marks a significant step forward in addressing the unmet needs of patients suffering from TD, a potentially irreversible movement disorder commonly associated with long-term use of antipsychotic medications.
Tardive Dyskinesia is characterized by involuntary, repetitive movements, often affecting the face, tongue, and limbs. It can be a debilitating side effect for patients undergoing treatment for psychiatric disorders such as schizophrenia and bipolar disorder. Current therapies primarily focus on managing symptoms rather than offering a cure, and there is a strong demand for more effective and tolerable treatments.
Serina’s approach centers on the development of a new vesicular monoamine transporter 2 inhibitor (VMAT2i), a class of drugs that modulate the release of certain neurotransmitters involved in movement regulation. What sets Serina’s candidate apart is its proprietary POZ (polyoxazoline) drug delivery technology. This platform enables the creation of novel drug conjugates with improved pharmacokinetic profiles—meaning the drugs stay active in the body for longer periods and may offer more consistent therapeutic effects.
The POZ-VMAT2i conjugate is designed to maintain stable drug levels, potentially reducing dosing frequency and side effects commonly seen with current VMAT2 inhibitors. According to Serina Therapeutics, preclinical studies have shown promising results, with the candidate exhibiting efficacy in relevant animal models and a favorable safety profile. These findings support the transition to human clinical trials, where the drug’s safety, tolerability, and effectiveness will be further evaluated.
The company’s CEO, Dr. Randall Moreadith, expressed optimism about the POZ-VMAT2i program, highlighting the potential benefits for patients living with TD. He emphasized Serina’s commitment to leveraging its POZ technology to improve the treatment landscape for neurological and neuropsychiatric disorders. The advancement into clinical development not only demonstrates the promise of the company’s scientific approach but also sets the stage for potential collaborations and partnerships as the candidate progresses through the clinical pipeline.
